Stock Ratings / Health Care / KPRX / forecast

TCRT (31) CURX (37) UPC (33) MTVA (47) ⌘ Pro Terminal →

Kiora Pharmaceuticals Inc. (KPRX) 12-Month Stock Forecast & Price Target Cone

Q: Is KPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.76 (-25.42% 1D, market cap $7.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KPRX ranks #902 in composite RQD confidence.

Q: How does KPRX compare to TCRT and CURX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPRX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M) and CURX (Curanex Pharmaceuticals Inc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M). Among the 5-stock peer group, KPRX leads on earnings multiple (N/A) while KPRX leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for KPRX?

Per KPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372514), Kiora Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$10.8K in net income, and -$10.1M in free cash flow against $24.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is KPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

KPRX last traded at $1.76 (-25.42% on volume of 490,625 shares), positioning the stock -29.60% below its 50-day simple moving average ($2.50) and -26.97% below its 200-day simple moving average ($2.41). Across its 52-week range of $1.55 to $2.91, KPRX sits at the 15.4% percentile with a 14-day RSI of 17.1 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.57 to $1.95).

Q: What is KPRX's 12-month stock price target?

Kiora Pharmaceuticals Inc. (KPRX) carries a 12-month consensus base price target of $1.55 (-11.9% from $1.76), with a bull-case target of $3.06 and a bear-case floor of $1.21.

Q: Is KPRX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates KPRX E (Strong Sell — SELL) with an RQD Confidence score of 32/100.

$1.76 -25.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.68

Kiora Pharmaceuticals Inc. (KPRX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $7.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.68 (-4.77%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KPRX)Realized 20D OHLCV Swing Band: ±10.7%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY KPRX SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (31% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 17.1 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.54-5.5% Next Q

Q2 (-2Q)

Grade E$2.40-4.6% Next Q

Q3 (-1Q)

Grade E$2.29-23.1% Next Q

Current

Grade E$1.76-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KPRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KPRX currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.50) and Max Pain ($1.85) forces dealer call-delta covering toward $3.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KPRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your KPRX Position Size: $10,000

Shares at $1.76: 5681.8 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.21

$6,875

$-3,125 (-31.3%)

12M Consensus BaseTarget $1.55

$8,807

$-1,193 (-11.9%)

12M Bull Case BreakoutTarget $3.06

$17,386

+$7,386 (+73.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KPRX)

✓Walkthrough of KPRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.11%▼ SUPPORT BREAKDOWN

2026-10-30O $1.78H $1.83L $1.55C $1.76VOL 100.7K

RES: $2.92SUP: $1.90SMA50: $2.50SMA200: $2.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KPRX Butterfly Map → + Track KPRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KPRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KPRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KPRX)

Health Care Rank #902 of 1016 ⚔️ TCRT vs KPRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KPRX vs. TCRT, CURX, UPC, MTVA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kiora Pharmaceuticals Inc. (KPRX) ranks #902 by composite RQD confidence (32/100, grade E) and #915 by equity capitalization ($7.8M). Within this direct 5-issuer industry benchmark cohort, KPRX leads on earnings valuation at N/A trailing P/E, while KPRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MTVA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with KPRX at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KPRX ACTIVE Kiora Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	-25.42%	$7.8M	Benchmark Subject
TCRT Alaunos Therapeutics Inc.	E	31/100	—	—	-35.0%	-11.27%	$7.8M	/tcrt-vs-kprx →
CURX Curanex Pharmaceuticals Inc	D-	37/100	—	—	-35.0%	-0.20%	$7.7M	/curx-vs-kprx →
UPC Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-20.21%	$7.7M	/upc-vs-kprx →
MTVA MetaVia Inc.	D	47/100	—	—	-35.0%	+4.39%	$7.8M	/mtva-vs-kprx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001372514

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kiora Pharmaceuticals Inc. (KPRX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $16.0M ) , GAAP net income of -$10.8K, operating cash flow of -$10.0M, and free cash flow of -$10.1M (-217.8% YoY). On the balance sheet, KPRX closed FY2025 with $24.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.8K	-$10.0M	-$10.1M	$24.3M	—
FY2024 (FY)	2024-12-31	$16.0M	$3.6K	$8.6M	$8.6M	$36.5M	—
FY2023 (FY)	2023-12-31	$0	-$12.5K	-$9.6M	-$9.6M	—	—

3. KPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.76 (-25.42% 1D, market cap $7.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KPRX ranks #902 in composite RQD confidence.

How does KPRX compare to TCRT and CURX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPRX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M) and CURX (Curanex Pharmaceuticals Inc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M). Among the 5-stock peer group, KPRX leads on earnings multiple (N/A) while KPRX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KPRX?

Per KPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372514), Kiora Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$10.8K in net income, and -$10.1M in free cash flow against $24.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

KPRX last traded at $1.76 (-25.42% on volume of 490,625 shares), positioning the stock -29.60% below its 50-day simple moving average ($2.50) and -26.97% below its 200-day simple moving average ($2.41). Across its 52-week range of $1.55 to $2.91, KPRX sits at the 15.4% percentile with a 14-day RSI of 17.1 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.57 to $1.95).

KPRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is KPRX's 12-month stock price target?

Kiora Pharmaceuticals Inc. (KPRX) carries a 12-month consensus base price target of $1.55 (-11.9% from $1.76), with a bull-case target of $3.06 and a bear-case floor of $1.21.

Is KPRX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates KPRX E (Strong Sell — SELL) with an RQD Confidence score of 32/100.

Direct Sub-Reports: KPRX RQD Cockpit KPRX 12M Forecast KPRX Earnings & Move KPRX Dividends & DRIP KPRX Insiders & 13F KPRX Whale Options KPRX Profit Sankey KPRX News & Why